23.79
1.33%
-0.32
Pre-market:
25.00
1.21
+5.09%
Beam Therapeutics Inc stock is currently priced at $23.79, with a 24-hour trading volume of 591.69K.
It has seen a -1.33% decreased in the last 24 hours and a -7.43% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $24.57 pivot point. If it approaches the $23.51 support level, significant changes may occur.
Previous Close:
$24.11
Open:
$24.04
24h Volume:
591.69K
Market Cap:
$1.96B
Revenue:
$377.71M
Net Income/Loss:
$-132.53M
P/E Ratio:
-5.2749
EPS:
-4.51
Net Cash Flow:
$-182.93M
1W Performance:
+5.55%
1M Performance:
-7.43%
6M Performance:
-4.03%
1Y Performance:
-29.74%
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857 327 8775
Address
26 Landsdowne Street, 2nd Floor, Cambridge, MA
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Dec-13-22 | Initiated | Citigroup | Buy |
Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Jan-05-22 | Initiated | Guggenheim | Buy |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Sep-24-21 | Resumed | Stifel | Buy |
Sep-10-21 | Initiated | BofA Securities | Buy |
May-11-21 | Initiated | Redburn | Buy |
May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-16-21 | Initiated | Wells Fargo | Overweight |
Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-06-21 | Initiated | Stifel | Hold |
Aug-05-20 | Initiated | William Blair | Outperform |
Mar-02-20 | Initiated | Barclays | Overweight |
Mar-02-20 | Initiated | JP Morgan | Overweight |
Mar-02-20 | Initiated | Jefferies | Buy |
Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Short Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Increases By 6.5% - MarketBeat
MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
MarketBeat
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European ... - Yahoo Canada Finance
Yahoo Canada Finance
Beam Therapeutics (NASDAQ:BEAM) Trading Up 10.1% - MarketBeat
MarketBeat
Cantor Fitzgerald Weighs in on Beam Therapeutics Inc.'s FY2024 Earnings (NASDAQ:BEAM) - MarketBeat
MarketBeat
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn - Simply Wall St
Simply Wall St
Beam Therapeutics Inc Stock (BEAM) Financials Data
Beam Therapeutics Inc (BEAM) Revenue 2024
BEAM reported a revenue (TTM) of $377.71 million for the quarter ending December 31, 2023, a +520.01% rise year-over-year.
Beam Therapeutics Inc (BEAM) Net Income 2024
BEAM net income (TTM) was -$132.53 million for the quarter ending December 31, 2023, a +54.16% increase year-over-year.
Beam Therapeutics Inc (BEAM) Cash Flow 2024
BEAM recorded a free cash flow (TTM) of -$182.93 million for the quarter ending December 31, 2023, a -592.28% decrease year-over-year.
Beam Therapeutics Inc (BEAM) Earnings per Share 2024
BEAM earnings per share (TTM) was -$1.90 for the quarter ending December 31, 2023, a +54.00% growth year-over-year.
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Cap:
|
Volume (24h):